|MDACC Study No:||2013-0090 (clinicaltrials.gov NCT No: NCT01880567)|
|Title:||A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients with Newly Diagnosed MCL|
|Principal Investigator:||Michael Wang|
|Treatment Agent:||Ibrutinib; Rituximab|
|Study Description:||The goal of this clinical research study is to learn if a combination of |
ibrutinib and rituximab can help control MCL in patients with relapsed or
refractory disease or in patients over 65 who have newly diagnosed MCL. The
safety of this drug combination will also be studied.